semaglutide and prostate cancer In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival Lutetium‑177 PSMA Therapy for Prostate

Approximately 6 days, based on pharmacokinetic data from Eli Lillys Phase 2 clinical trials

But these findings have not been confirmed in humans

In contrast, but with ultimately the same result, impairment of transsulfuration will lead to increased intracellular SAM concentrations and consequent inhibition of MTHFR, which reduces the formation of 5-methyltetrahydrofolate for remethylation and inhibits recycling of homocysteine through its conversion to methionine (16)

But the question nonetheless stands

Because both forms are fast-acting, doctors usually choose the method based on safety, availability, and how predictable the response needs to be

I have been using it for a month now and I have no complaints